tirzepatide eli lily Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Lilly's tirzepatide slashes risk of
Description
If a small drop of blood appears, press with a clean cotton ball
Long-term data confirm robust effects on mortality, cardiometabolic outcomes, renal disease, T2D progression, musculoskeletal function, sleep apnea, liver disease, and cancer risk
In SURPASS clinical trials, tirzepatide reduced the A1C by about 1.8 to 2.1% on average with 5 mg once weekly, while metformin reduced glycated hemoglobin levels by 1% to 1.5% after 3-6 months
Most of those claims collapse under scrutiny
